Bridge to Industry | Challenges and Solutions in Life Sciences

You are invited to the fifth lecture in the “Bridge to Industry” series: Insights from Developing Novel Allogeneic Cell Therapies for Serious Neurological and Ophthalmic Diseases

Speaker: Dr. Rami Skaliter, CEO of Cellucure Neurosciences Ltd

Dr. Skaliter has an extensive career in the life sciences and pharmaceutical industries, specializing in drug development. He holds a B.Sc. in Biology from Ben-Gurion University and an M.Sc. and Ph.D. in Biochemistry from the Weizmann Institute, where he focused on DNA replication and mutagenesis. After completing a postdoctoral fellowship at Stanford University, he transitioned into the biotech industry.

He currently serves as the CEO of Cell Cure Neurosciences, an Israeli subsidiary of Lineage Cell Therapeutics, dedicated to developing and manufacturing pluripotent stem cell–derived therapies for degenerative eye diseases and other neurodegenerative conditions. Previously, he spent more than 20 years in key roles at Quark Pharmaceuticals, including a decade as Chief Operating Officer.

At CellCure, he leads the development of scalable GMP manufacturing processes for allogeneic cell therapies, including RPE cells for Dry AMD (in collaboration with Genentech/Roche) and auditory neuron progenitors for Auditory Neuropathy (in partnership with Demant), alongside additional therapeutic programs. He has been a speaker at major industry conferences, presenting on cell therapy formulation, immune rejection challenges, and advancing stem cell–based therapies into clinical trials.

Date: Wednesday, December 24, at 13:00
Location: Biology Auditorium

Schedule:
12:30–13:00 Coffee and light refreshments – Lobby outside the auditorium
13:00–14:00 Seminar – Biology Auditorium
14:00–14:30 Open discussion with the speaker on “Bridge to Industry” – Auditorium Lobby

Join us for a fascinating journey of discovery, collaboration, and innovation!